The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

The programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, which evaluated icotrokinra, an oral peptide, in treating plaque psoriasis (PsO). The randomised clinical trial ...

An analysis of a large general practice database showed that patients with severe plaque psoriasis for 3-6 years had a 50% higher relative risk of premature mortality. On average, men and women ...

Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with placebo at week 12. The safety profile of ICP-488 was similar to placebo. ORLANDO — A once ...

Share on Pinterest Super Bowl LIX champion Dallas Goedert of the Philadelphia Eagles shares his journey with plaque psoriasis, an autoimmune skin condition. Brooke Sutton/Getty Images Super Bowl ...

Hormonal fluctuations during pregnancy can trigger psoriasis in approximately 10-20% of women, stated health experts (1 Trusted Source Can a woman treat psoriasis while pregnant or breastfeeding?

Plaque psoriasis, a chronic autoimmune disorder that causes thick, scaly, itchy patches—the eponymous plaques—to form on the skin, affects more than 7.5 million adults in the United States.

On Oct. 1, actress and media personality La La Anthony shared her ongoing struggle with plaque psoriasis on Instagram ... unique challenges for Black women who often wear protective styles ...

Over 6 million adults in the U.S. live with plaque psoriasis, yet many misunderstand the disease. Dr. Meagen McCusker and La La Anthony discuss its impact to raise awareness. #PaidForContent ...

An improvement of 75% or greater in Psoriasis Area and Severity Index scores were achieved by week 12 of treatment among patients with moderate to severe plaque psoriasis receiving zasocitinib in ...